Approval of Multiple Oncology Products by FDA

The FDA's announcement covers the approvals of daraxonrasib for metastatic pancreatic adenocarcinoma, zanidatamab-hrii and tislelizumab-jsgr for HER2-positive cancers, and the accelerated approvals of iberdomide and vusolimogene oderparepvec-wtpg for multiple myeloma and melanoma, respectively.

What changed: The FDA clarified its reporting requirements and approach to approval notifications for oncology and hematology products, specifying that not all approvals or label updates will be publicly announced.

Why it matters: Understanding these changes is critical for ensuring compliance with regulatory obligations and accurately reporting on drug approvals, which affects market access and safety monitoring for new treatments.

Practical implication: Review and update internal compliance and reporting workflows to align with the FDA's reporting requirements for the latest oncology product approvals.

• Recalls, Market Withdrawals and Safety Alerts
• Warning Letters
• Safety
• Inspections and Compliance
• FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer
• Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase
• FDA approves daratumumab and hyaluronidase-fihj for high-risk smoldering multiple myeloma
• FDA approves mitomycin intravesical solution for recurrent low-grade intermediate-risk non-muscle invasive bladder cance

• Oncology (Cancer)/Hematologic Malignancies Approval ...
• An analysis of FDA drug approvals for oncological ... - PMC
• Drug Approvals and Databases

View original source

• Source: FDA - Drug Approvals and Databases
• Published at source: 2026-08-26T00:00:00.000Z
• Discovered by monitor: 2026-08-26T23:42:15.094Z

Published from the regulator source ingestion pipeline after PV impact triage.